An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma
A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler Compared With Usual Maintenance Therapy in Subjects With Asthma
Sponsor: GlaxoSmithKline
Listed as NCT01706198, this PHASE3 trial focuses on Asthma and remains completed. Sponsored by GlaxoSmithKline, it has been updated 8 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Dec 2017 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Altrincham, United Kingdom , Bowdon, United Kingdom , Broadway, Davyhulme, United Kingdom , Cadishead, Manchester, United Kingdom , Cheadle, United Kingdom , Cheadle Hulme, United Kingdom , Eccles, United Kingdom , Eccles, Manchester, United Kingdom , Edgeley, United Kingdom , Ellenbrook, Manchester, United Kingdom and 24 more locations